Announcements Trials
Browse Landscape

Status

Completed 43Terminated 29Recruiting 29Active not recruiting 24Withdrawn 6Unknown 6Not yet recruiting 6Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Recurrence 11Carcinoma, Non-Small-Cell Lung 11Neoplasms 8Prostatic Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Leukemia, Myeloid, Acute 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lambert-Eaton Myasthenic Syndrome 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Myasthenic Syndromes, Congenital 2Lymphoma 2Liver Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Head and Neck Neoplasms 2

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × Carcinoma, Merkel Cell × Clear all
NCT03089658 2019-10-09

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Merck KGaA, Darmstadt, Germany

Approved for marketing
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡